StrataGraft market projected to grow as burn injuries and regenerative medicine rise

The Business Research Company says the StrataGraft market is expanding on the back of more burn injuries, stronger demand for advanced wound care, and increasing regenerative medicine research. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region through the forecast period.

Why it matters: - StrataGraft sits in a growing market for advanced burn care and skin substitutes. - Demand is being shaped by more burn injuries, chronic wounds, and wider use of regenerative medicine. - The trend matters because StrataGraft is positioned as an alternative to traditional grafting and donor-site procedures.

What happened: - The Business Research Company published a new StrataGraft market analysis on November 12, 2026. - The report says the market is gaining traction as regenerative medicine advances and burn injury cases increase. - The analysis includes market size, growth drivers, regional share, and forecast trends. - The company also offered a free sample of the StrataGraft market report.

The details: - StrataGraft is a bioengineered, allogeneic skin substitute designed for deep partial-thickness burns and other complex skin defects. - The product includes both dermal and epidermal layers. - Human keratinocytes and dermal fibroblasts are cultivated on a collagen scaffold to create the structure. - The design is meant to mimic natural skin layers and support wound repair and regeneration. - The historical market was supported by more burn injuries, progress in tissue engineering research, broader adoption of allogeneic skin substitutes, higher investment in regenerative medicine, and better clinical outcomes in burn care. - Future growth is expected to come from more regenerative medicine approvals, higher demand for advanced wound care products, more investment in bioengineered tissue platforms, outpatient burn treatment options, and continued skin substitute innovation. - The company expects key trends to include broader acceptance of bioengineered skin substitutes, higher demand for advanced burn care solutions, more regenerative wound healing therapies, growth in collagen-based scaffold technologies, and efforts to reduce reliance on autografts. - The report says rising chronic wounds and burn injuries are a major demand driver. - Diabetes, poor circulation, obesity, aging populations, industrial accidents, and limited preventive care contribute to chronic wounds and burn-related demand. - StrataGraft is presented as an advanced alternative to traditional skin grafts that can support healing and reduce the need for donor site procedures. - The World Health Organization said in October 2023 that burn injuries cause about 180,000 deaths globally each year, mostly in low- and middle-income countries. - The United States recorded about 410,000 burn injuries in 2023, and 40,000 required hospitalization. - The report says more clinical trials are helping advance StrataGraft by building evidence on safety and effectiveness. - The Association of the British Pharmaceutical Industry said industry-sponsored clinical trials in the UK rose from 411 in 2022 to 426 in 2023. - The report also links market growth to higher healthcare spending, which supports infrastructure, access, and development of advanced wound care. - The Canadian Institute for Health Information projected Canadian health spending to rise 2.8% in 2023, compared with 1.5% growth in 2022. - In 2025, North America held the largest share of the StrataGraft market. - The report says Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The regional coverage also includes Western Europe, Eastern Europe, South America, the Middle East, and Africa. - The 2026 report format includes market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and key technology and future trend analysis.

Between the lines: - The market narrative is less about one product and more about a broader shift toward regenerative wound care. - Stronger clinical evidence and public health pressure around burns could help push adoption beyond specialized centers. - Regional growth outside North America suggests the commercial opportunity is widening as healthcare investment expands.

What's next: - The market outlook points to continued growth if regenerative medicine approvals and advanced wound care adoption keep increasing. - Asia-Pacific bears watching as healthcare investment and patient volume rise. - Further clinical trial data will likely remain central to broader use and regulatory momentum.

The bottom line: - StrataGraft is moving into a larger market shaped by burn burden, regenerative medicine, and demand for alternatives to traditional grafting.